Compare GRRR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRRR | CBIO |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 252.6M |
| IPO Year | N/A | N/A |
| Metric | GRRR | CBIO |
|---|---|---|
| Price | $13.17 | $13.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $25.60 |
| AVG Volume (30 Days) | ★ 1.2M | 56.4K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,747,682.00 | N/A |
| Revenue This Year | $36.14 | N/A |
| Revenue Next Year | $27.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.86 | N/A |
| 52 Week Low | $5.75 | $9.81 |
| 52 Week High | $44.15 | $21.40 |
| Indicator | GRRR | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 47.84 |
| Support Level | $13.00 | $12.76 |
| Resistance Level | $13.83 | $15.40 |
| Average True Range (ATR) | 1.04 | 0.73 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 27.55 | 17.83 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.